Hyperkalemia in Elderly Patients Receiving Standard Doses of Trimethoprim-Sulfamethoxazole
To the Editors: Greenberg and colleagues (1) ascribed the hyperkalemia found in some human immunodeficiency virus (HlV)-infected patients treated with high-dose trimethoprim to the drug's similarity to amiloride (2) . Recently, we saw a patient without the acquired immunodeficiency syndrome (AIDS) who developed hyperkalemia while receiving standard doses of trimethoprim.
This patient, a healthy, active 72-year-old woman with a history of nonprogressive sarcoidosis not requiring medication and mild reactive airway disease treated as needed with an albuterol inhaler was hospitalized with tracheobronchitis and worsening of her reactive airway disease. Laboratory findings at admission were normal, with normal electrolytes (potassium, 4.8 mmol/L), normal renal function (blood urea nitrogen, 8 mg/dL; creatinine, 0.6 mg/dL), and a pH of 7.4. She was given trimethoprim, 160 mg, and sulfamethoxazole, 800 mg (one double-strength tablet), twice daily, and inhaled albuterol. After 2 days, albuterol treatment was discontinued. Her potassium level was then found to be 5.7 mmol/L and remained between 5.7 and 6.0 mmol/L for 4 more days while on a diet that did not include excessive potassium and despite vigorous hydration with intravenous normal saline. Her urinary sediment remained normal, as did her other electrolytes and renal function. The day after therapy with trimethoprim-sulfamethoxazole was discontinued, her potassium level returned to 4.4 mmol/L. During the next week, her potassium level remained at 4.8 mmol/L.
The temporal association of trimethoprim use with hyperkalemia in this patient strongly suggests a causal role. As noted, hyperkalemia could not be explained by volume depletion, renal failure, interstitial nephritis, acidosis, diet, or other medications. It would be interesting to see if this association is confirmed in a large clinical trial, especially in older persons with some degree of age-related renal insufficiency. 
To the Editors:
We read with great interest the recently reported (1) association between high-dose trimethoprim-sulfamethoxazole therapy and hyperkalemia seen in patients with AIDS. Although our patient population differs substantially from that studied by Greenberg and colleagues (1), we have seen a similar clinical course evolve in an elderly, cognitively impaired patient who was being treated for a urinary tract infection. Our patient, a 76-year-old woman, presented with normal serum electrolyte levels (sodium, 136 mmol/L; potassium, 4.5 mmol/L; HC0 3 , 24 mmol/L; chlorine, 108 mmol/L; blood urea nitrogen, 23 mg/dL; and creatinine, 1.1 mg/dL) and no known history of renal, endocrine, or metabolic abnormalities. At admission, urinalysis was similarly unremarkable with the exception of pyuria and bacteruria. Subsequent culture yielded a pan-sensitive Klebsiella species, and the patient was given trimethoprim-sulfamethoxazole (Septra-DS; Burroughs Wellcome, Research Triangle Park, North Carolina), one tablet twice daily, beginning on hospital day 3. One week later, her mental status declined acutely, and her electrolytes showed a serum potassium level of 6.2 mmol/L, without evidence of azotemia, acidosis, or dehydration. The patient had not received airy other known nephrotoxic medications during this period. Her urinary sediment continued to be unremarkable. Therapy with trimethoprim-sulfamethoxazole was discontinued, and the patient was treated with one dose of kayexalate. Her serum potassium level returned to normal and remained so for the duration of her 3-week hospitalization.
To our knowledge, no available data exist on the incidence of hyperkalemia in geriatric patients receiving standard adult doses of this commonly used antibiotic. Although the mechanism by which trimethoprim-sulfamethoxazole induces hyperkalemia remains unclear, does the age-associated decrease in the glomerular filtration rate place our elderly patients at higher risk for a dose-dependent, potentially fatal complication? Until additional data are available, we suggest using this antibiotic treatment with greater caution in elderly patients.
tively, every 12 hours (total, 6.5 mg/kg per day) for four doses, followed by an oral preparation at the same dose. Her serum potassium concentration, which at admission had been 3.6 mmol/L, increased progressively to 5.3 mmol/L by 72 hours of trimethoprim-sulfamethoxazole therapy. Therapy was changed to amoxicillin, and her potassium level dropped to 4.6 mmol/L within 24 hours.
Therapy with trimethoprim-sulfamethoxazole was resumed after a 24-hour period, and, within 36 hours, her serum potassium concentration again rose to 5.3 mmol/L. Because of this reproducible increase in serum potassium concentration, amoxicillin was substituted for the duration of treatment. Eleven days after discharge, her potassium concentration had fallen to 4.5 mmol/L. Of note, her serum creatinine concentration during her hospitalization was 0.8 mg/dL, and her estimated creatinine clearance (from the modified Cockcroft-Gault equation) was 32 mL/min. While in the hospital, except for the antibiotics and a 50-mEq supplement of potassium chloride given intravenously during the first 24 hours, the patient received only her usual outpatient medications.
This case suggests that in some patients, standard doses of trimethoprim-sulfamethoxazole (one double-strength tablet twice daily) can raise the serum potassium concentration. This dose is less than half of that commonly used to treat Pneumocystis carinii pneumonia (1). Medina and colleagues (1) noted that hyperkalemia developed in 20% of patients receiving highdose trimethoprim-sulfamethoxazole (20 mg/kg per day of trimethoprim) for P. carinii pneumonia. Greenberg and colleagues (2) also documented a reversible rise in serum potassium concentrations with high-dose trimethoprim-sulfamethoxazole therapy. Clinicians should be alert to the possibility of hyperkalemia in patients receiving standard doses of this antibiotic. In response: Before receiving the above correspondence, we were unaware of any case reports in which administration of trimethoprim-sulfamethoxazole in standard doses (160 mg of trimethoprim and 800 mg of sulfamethoxazole given twice daily) has been implicated as a cause of hyperkalemia. In fact, of the 649 patients who received trimethoprim-sulfamethoxazole in standard doses and who were monitored within a hospital setting in the Boston Collaborative Drug Surveillance Program, none developed hyperkalemia (1). Trimethoprim-sulfamethoxazole inhibits amiloride-sensitive sodium channels in the distal nephron and reduces the transepithelial voltage favoring potassium secretion in a dose-dependent fashion (2, 3) . Standard twice-daily doses of trimethoprim-sulfamethoxazole may not maximally inhibit renal potassium excretion because the achievable urinary drug concentrations may only produce a 50% decrease in the electrical gradient (2, 3) . Other factors such as age-related reductions in renal function or defects in renal potassium handling may be required for standard doses of trimethoprim-sulfamethoxazole to express fully the hyperkalemic effect. Prospective studies are needed to examine this possibility. 
David

Weaning Patients from Mechanical Ventilation Using Gastric pH
To the Editors: Mohsenifar and colleagues (1) reported that tissue acidosis, as reflected by a very low gastric intramural pH, accurately predicted failure to wean patients from mechanical ventilation.
The authors used the H C03 , P CQ2 , and pH from arterial blood gas analysis plus gastric P C02 (Pgco 2 ) and the p co 2 factor in the Henderson-Hasselbach equation to calculate gastric intramural pH (1). Substitution and rearrangement permit cancellation of the H co , and P COl factor terms. The simpler revised formula is: gastric intramural pH = arterial pH -log[Pg co /Pa c02 ].
Both before and during weaning, arterial pH and ra cc , 2 were virtually identical in the weaning success and failure groups (1). Because gastric P CQ2 is the principal determinant of gastric intramural pH, would prediction of weaning outcome be as accurate using Pgco 2 alone? What are the sources of error in measuring gastric -Pco 2 ? What effect does hypotension or low cardiac output have on gastric P CQ2 , independent of weaning?
The mechanism of tissue acidosis could be increased respiratory muscle blood flow at the expense of other organs, especially the splanchnic bed. In animal models of cardiogenic and septic shock, respiratory muscle blood flow ranged from 10% to 20% of cardiac output (2, 3) . Mechanical ventilation lowered respiratory muscle blood flow and made 30% to 50% more blood flow available to the brain and splanchnic bed; however, the patients studied by Mohsenifar and colleagues were normotensive and hemodynamically stable. One therefore would have to seek other explanations for their poor splanchnic perfusion.
Dudley F. Rochester, MD University of Virginia Health Sciences Center Charlottesville, VA 22908
To the Editors: In contrast to our finding (1), Mohsenifar and colleagues (2) found respiratory frequency, tidal volume, and the ratio of frequency/tidal volume to be poor predictors of weaning failure. In their important paper on the methodologic standards used in studies of predictive indexes, Wasson and colleagues (3) emphasized the need for investigators to follow the original protocol, but Mohsenifar and associates fell short. First, frequency and tidal volume were measured at 20 to 30 minutes into the weaning trial rather than at the beginning of the trial. Second, they failed to indicate 1) the instrumentation used to measure tidal volume; 2) the sampling period; or 3) the gas being inhaled. Third, they measured frequency and tidal volume during pressure support of "about 7 to 8 cm H 2 0," a level judged to overcome resistance of the endotracheal tube and circuit. However, as they reported, this level markedly overcompensates, causing a 39% decrease in work of breathing and a decrease in the ratio of frequency/tidal volume of 14 breaths/min per litre (4). Thus, it is hardly surprising that the ratio measured during pressure support but using the threshold value derived during spontaneous breathing was inaccurate in predicting weaning failure. Fourth, frequency, tidal volume, and the ratio of frequency/tidal volume were prospectively tested, whereas gastric pH was evaluated in a post hoc manner, which can markedly overestimate the accuracy of a predictive index (3). In response: Dr. Rochester raises several interesting questions and makes many insightful comments. Gastric P co is the main determinant of gastric intramural pH. As we stated (1), a rising gastric P C o 2 would have predicted 9 of 11 weaning failures and an elevated baseline gastric P C o 2 would have predicted the remaining 2 failures. Independent of weaning, hypotension or low cardiac states would be expected to be detrimental to splanchnic blood flow, which would eventually result in a rise in gastric C0 2 . Dead space in the nasogastric tube and bicarbonate flux are possible sources of error in measuring real-time gastric P COr We believe that the blood flow demanded by the respiratory pump to support the excessive work of breathing during weaning trials was primarily responsible for the redistribution of blood flow from the splanchnic bed. Such diversion can occur in states other than hypotension or low cardiac output. In an animal model of oleic acid-induced pulmonary edema, Magder and colleagues (2) reported significantly increased respiratory muscle blood flow, coupled with a reduction in splanchnic blood flow without a significant decrease in blood pressure. In support of our hypothesis, three patients who failed weaning trials had restoration of gastric intramural pH to normal when assisted mechanical ventilation was resumed.
We will respond to Dr. Tobin's major points: We designed our study to investigate the utility of gastric intramural pH in predicting weaning success or failure and clearly stated that our protocol differed from Yang and Tobin's (3). Of interest, Lee and colleagues (4) found the ratio of frequency/tidal volume not to be highly predictive using their protocol.
As stated (1), we used a 7200 A ventilator (Puritan-Bennett, Carlsbad, California), which measures BTPS-corrected tidal volume using an eight-breath running average. All patients received the same FI0 2 as that was provided by assisted mechanical ventilation.
Nathan and colleagues (5) found an overcompensation of pressure support related to upper airway obstruction and increased work of breathing after extubation. The level of pressure support (7 to 8 cm H 2 0), calculated based on the product of airway resistance and peak spontaneous flow rate, has been reported to overcome the added respiratory work resulting from an endotracheal tube and circuit resistance (6) .
Patients were managed in a standard way by physicians blinded to the results of gastric intramural pH and gastric P CQ2 to prevent any bias. Of importance, however, they showed a high false-positive rate (even in Yang and Tobin's report), which unfortunately results in failed extubations. To the Editors: Series and colleagues (1) concluded that nocturnal home oximetry screening in patients suspected to have the obstructive sleep apnea-hypopnea syndrome would decrease the number of patients who required complete polysomnographic monitoring. They suggested, however, that because of its low specificity and consequent low positive predictive value, positive home oximetry must be followed by complete polysomnographic monitoring. They studied 240 outpatients referred because of reported sleep disturbances or daytime hypersomnia and confirmed the syndrome in 110. The diagnosis and follow-up of the remaining 130 patients were not defined by the study.
Patients not found to have the syndrome represent an equally important group. Daytime sleepiness, even in the absence of sleep apnea, is not a trivial complaint. Narcolepsy, idiopathic central nervous system hypersomnia, periodic leg movement disorder, and the insufficient sleep syndrome are significant disorders that may also occur in individuals with concomitant snoring. Nocturnal polysomnography with multiple sleep latency testing is necessary in these patients to establish a diagnosis.
In our opinion, nocturnal polysomnography and multiple Hypersomnolent patients do not seek medical expertise to rule out obstructive sleep apnea but rather to accurately diagnose the cause of their daytime sleepiness and have it corrected. Finally, because obstructive sleep apnea is not the most common cause of excessive daytime sleepiness (5), strategies aimed at evaluating only obstructive sleep apnea are likely to be ineffective.
In response: Both correspondents question the utility of nocturnal home oximetry in identifying the cause of excessive daytime sleepiness. We agree that diurnal hypersomnolence can be a major clinical manifestation of several diseases. Our study, however, was not designed to evaluate nocturnal oximetry in patients with hypersomnia but in patients suspected of having the sleep apnea-hypopnea syndrome. In our experience and that of others, no correlation exists between the respiratory disturbances index and daytime sleepiness (2), which is present in fewer than 30% of patients with mild to moderate sleep apnea-hypopnea syndrome (3). In men 30 to 60 years of age, the estimated prevalence of sleep-related abnormal breathing is 24%; only 22.6% of these patients have hypersomnolence (4). We agree that our results cannot be extended to the general evaluation of patients reporting excessive daytime sleepiness.
Concerning the utility of nocturnal oximetry in the presence of sleep fragmentation caused by other sleep-related breathing disorders (such as the upper airway resistance syndrome), we found that 76% of patients with this syndrome had an abnormal oximetry recording consisting of small and regular desaturations. This finding confirms previous results that showed small changes in oxyhemoglobin arterial saturation when upper airway resistance increases (5). A polysomnographic study combined with a multiple sleep latency test represents the gold standard in the evaluation of the sleep apnea-hypopnea syndrome; however, because of the dramatic increase in the number of patients who are referred for sleep disturbances, it is the responsibility of sleep centers to develop and validate shorter diagnostic methods and pretest evaluations to select patients needing complete sleep studies. We strongly believe that nocturnal home oximetry can play an important part in such strategies. We agree that patients whose complaint is primary hypersomnolence require complete sleep studies. In response: Drs. Salomon, Perlman, and Goldstein present their experience with ofloxacin, ethambutol, and an aminoglycoside in HIV-infected patients with tuberculosis who developed hepatotoxicity while receiving standard antituberculous therapy. My limited experience with this combination therapy in patients with tuberculosis and without HIV infection also suggests that this regimen is adequate to keep the disease under control until the patient can tolerate more standard agents. We agree that additional evaluation of the microbiologic efficacy of this combination is needed.
I disagree with Dr. Johnson that corticosteroids should be used liberally in patients with tuberculous pericarditis because of methodologic concerns in the trial cited (1). This report combined results of two separate trials to obtain the groups who did and did not receive prednisolone. The baseline features were not reported for the placebo and prednisolone groups, so it remains uncertain whether the severity of pericarditis was similar. Finally, the lower death rate from pericarditis in patients treated with prednisolone (2 of 76 patients [3%] compared with 10 of 74 patients [14%]) has wide confidence intervals, despite its statistical significance. I believe that the findings in this and a previous trial (2) suggest that corticosteroids benefit a subpopulation of patients with tuberculous pericarditis. In the absence of any definitive evidence, I prefer to reserve treatment with corticosteroids for severely ill patients, in whom the benefit-to-risk ratio is likely to be high.
Peter Barnes, MD
University of Southern California School of Medicine Los Angeles, CA 90033
Hazard of Sauna Use after Strenuous Exercise
To the Editors: We report the occurrence of rhabdomyolysis and heart failure in a previously healthy person after exercise and sauna.
A 33-year-old man referred himself to our center because of dark urine. One day earlier, after strenuous exercise (primarily weight lifting), he sat in a sauna for approximately 15 minutes. Although he had done similar exercise irregularly before, he had never used the sauna immediately afterward. The next day, he had muscular soreness and noted dark urine. He denied previous illnesses and the intake of medications, drugs, or alcohol. Physical examination showed no distress, fever, or abnormal findings other than muscle tenderness. The urinalysis result was positive for blood by dipstick, but microscopy showed no erythrocytes. His serum creatine kinase was 39 720 IU/L; his serum electrolyte, urea, and creatinine levels were normal. An electrocardiogram was within normal limits.
To prevent renal failure from rhabdomyolysis (1), the patient received vigorous intravenous hydration at a rate of approximately 0.5 L/h. Over the ensuing 2 days, his renal function remained normal; physical examination showed edema, jugular venous distention, and weight gain. A chest radiograph revealed cardiomegaly and pulmonary edema. Echocardiography and radionuclide ventriculography showed moderate left ventricular function, with an ejection fraction of 46%; the right ventricle was enlarged, with an ejection fraction of 39%. Inferoapical hypokinesis was also evident. After discontinuation of fluids and administration of furosemide, all signs of heart failure resolved. Graded exercise testing yielded no evidence of metabolic myopathy (2), and isometric hand-grip exercise elicited a normal rise and decline in peripheral venous lactate (3). The patient has since returned to his normal activities and has remained well for the subsequent 6 months.
This case shows the development of rhabdomyolysis and cardiac failure in a healthy man after strenuous exercise followed by a sauna bath. Although sauna can cause heat exhaustion and rhabdomyolysis may follow exertional heat stroke, a MEDLINE search identified no similar reports. Because transient myocardial depression may follow heat stroke, caution should be used in the aggressive administration of fluids (4). Patients should be aware of the potentially harmful consequences of sauna use after vigorous exercise.
Fixed Drug Eruption and Pseudoephedrine
To the Editors: A suspected adverse drug experience related to a pseudoephedrine-containing product was reported to us and shared some features with the patient described by Cavanah and Ballas (1), who had a pseudoephedrine reaction presenting as the toxic shock syndrome.
A 41-year-old man presented with a history of four episodes of an unusual fixed drug eruption after using a pseudoephedrine-containing product over the preceding 19 years. The first two episodes occurred at 22 years of age when he developed intense pruritus of the fingers approximately 12 hours after the ingestion of pseudoephedrine tablets. This symptom was followed by severe redness, swelling, erythema, heat, and white papules of the fingers, most prominent on the distal phalanges. No concurrent systemic signs or symptoms were noted. The swelling subsided over 7 days and was followed by desquamation of the affected areas ("like a snake shedding its skin") lasting approximately 2 weeks. An identical sequence of events occurred on three subsequent occasions (3, 15, and 19 years later) in association with pseudoephedrine or pseudoephedrinecontaining products. In one instance, the exposure consisted of licking the spoon used to administer a cold medicine to one of his children. After these events resolved, the patient noted a transverse groove across each nail plate that started at the matrix and progressed distally with nail growth. The patient denied any active disease, including occurrences of Raynaud phenomenon or symptoms suggesting connective tissue disease.
The reported events are consistent with a fixed drug eruption in that a sharply localized dermatitis occurred at the same site each time the suspect agent was administered. The reason that a drug-induced skin reaction would localize to the distal phalanges is a matter of conjecture. Various medications have been associated with particular lesional distributions (2). Lesional keratinocytes at the site of fixed drug eruptions may lack the capacity to regulate intercellular adhesion molecule-1 and thereby promote lymphocyte accumulation in those areas. It is possible but unlikely that alpha-agonist effects on peripheral vasculature contributed to this condition because of the dosages used and the known pharmacologic profile of pseudoephedrine.
As in the patient described by Cavanah and Ballas, our patient had desquamation of the hands and multiple positive rechallenges but not systemic signs and symptoms. Fixed drug eruption and pseudoscarlatina with distal desquamation have been reported with pseudoephedrine (3, 4) . Transverse Beau lines can be seen after various illnesses, both systemic and local, including paronychia and periungual dermatitis (5).
of clinical teaching. Their findings reflect current practice in that patients are hospitalized mainly for technical procedures and interventions directed against catastrophic illnesses.
This analysis of an important medical conference reinforces previous observations made about the deficiencies of classroom-style teaching in a profession where hands-on, personalized care has always been central (3) . Although conferencestyle teaching provides some efficiencies (4), the principal feature of clinical education-aside from teaching-is lost when the team moves into the conference room. "New" teaching methods need to recapture the sense of immediacy that defines the patient-doctor relationship.
Questions Patients Should Ask about Laparoscopic Cholecystectomy
To the Editors: We congratulate the American College of Physicians for promulgating "Guidelines for the Treatment of Gallstones" (1) and Ransohoff and Gracie for their excellent review (2) .
As New York State's Medicare peer review organization and Medicaid utilization review agent, we have studied complications from laparoscopic cholecystectomy (3, 4) . Of the observed complications in this study, 8.8% were surgical, reflecting skills, judgment, and technique defects on the part of operating surgeons.
In a hospital-based study, hospitals confirmed complications in 11.9% of 2940 Medicare and 9.7% of 1108 Medicaid patients during 1991 (4). These rates are much higher than those reported in several published retrospective and prospective studies (5). Ransohoff and Gracie (2) appropriately advise caution in interpreting the published series, given the small number of open cholecystectomies.
We believe that several of the low mortality and low complication studies reflect the results obtained by well-trained, skilled, and experienced laparoscopists who carefully chose the patients. These excellent outcomes do not provide a good estimate of morbidity and mortality when this new technology was widely adopted in an environment lacking uniform requirements for rigorous training and experience.
We applaud the recommendation contained in the College's guidelines to the effect that "... the clinician and patient should determine the experience of the surgeons before choosing the laparoscopic route." To assist patients in assessing the experience and competency of their potential laparoscopic surgeon, in 1992 we instituted a toll-free hotline on laparoscopic cholecystectomy for Medicare and Medicaid beneficiaries. We specifically suggest that patients ask many questions before surgery, such as: Is the surgeon board-certified? Does the surgeon have hospital privileges to do open cholecystectomy? Was the surgeon formally trained in a recognized program in laparoscopic cholecystectomy? How many laparoscopic cholecystectomies did he or she do and what were the frequency and types of complications? Is there a formal hospital process to grant physicians' privileges to do laparoscopic cholecystectomies? Has the surgeon received full and unqualified privileges to do the procedure? Is the surgeon doing the procedure in other hospitals?
Raphael P. Nenner, MD Pascal James Imperato, MD Theodore O. Will, MA Island Peer Review Organization Lake Success, NY 11042
